Close Menu

NEW YORK – CareDx reported after the close of the market on Wednesday that its fourth quarter revenues rose 64 percent year over year, largely in line with the preliminary Q4 revenues the company reported in January.

For the three months ended Dec. 31, 2020, the molecular diagnostics company reported total revenues of $58.6 million, up from $35.8 million during the same period a year earlier and beating the average Wall Street estimate of $55.5 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.